No Data
No Data
No Data
No Data
No Data
Hyperlink (09989.HK) held a board meeting on April 29 to consider and approve the first quarter results
On April 16, GLONGHUI (09989.HK) announced that the company will hold a board meeting on April 29, 2024 (Monday) to consider and approve the Group's first quarter results for the three months ended March 31, 2024 and their publication.
Gelonghui FinanceApr 16 04:37 ET
Shenzhen Hepalink Receives Thai Approval for Blood Clot Drug Exarane
Shenzhen Hepalink Pharmaceutical Group's (HKG:9989, SHE:002399) enoxaparin sodium injection, Exarane, has been approved by the Thailand Food and Drug Administration for sales in the market, a Tuesday
MT NewswiresApr 2 06:56 ET
Hipry (09989.HK): EXARANE obtains approval from Thailand
On April 2, Gelonghui (09989.HK) announced that Exarane (one of the Group's leading drugs for enoxaparin sodium injections) produced by its wholly-owned subsidiary Shenzhen Tiandao Pharmaceutical Co., Ltd., has been approved for marketing by the Thai Food and Drug Administration. The announcement stated that with this approval, the ennoxaparin sodium formulation representing the Group Hypree will be sold in the Thai market, which will further increase the global market share of the Group's enoxaparin sodium preparations. The Group believes that this approval is another important achievement in implementing the international layout of the Group's pharmaceutical business, once again proving that the Group has entered overseas markets
Gelonghui FinanceApr 2 05:19 ET
Hapley (09989): A total of 1 billion yuan in preparation for impairment in 2023
Hyperlink (09989) issued an announcement that Shenzhen Haipuri Pharmaceutical Group Co., Ltd. (hereinafter referred to as the “Company”)...
Zhitong FinanceApr 2 00:24 ET
Hapley (09989) plans to carry out foreign exchange derivatives transactions for hedging purposes with a total value of no more than 350 million US dollars
Hipry (09989) issued an announcement. In order to reduce foreign exchange risk and enhance financial stability, Shenzhen Haipuri Pharmaceutical Group...
Zhitong FinanceApr 2 00:06 ET
Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Is Making Moderate Use Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Simply Wall StMar 29 20:35 ET
No Data
No Data